Amgen "neutral"

30.08.07 - Robert W. Baird

NEW YORK, August 30 (newratings.com) - Analyst Christopher J Raymond of Robert W Baird maintains his "neutral" rating on Amgen Inc (AMGN). The target price is set to $57.

In a research note published yesterday, the analyst mentions that a US Federal District Court has ruled that Roche's Mircera violates Amgen?s pivotal '422 EPO patent. Aranesp's revenues are expected to be impacted by potential ESA issues, like restrictions from private payers in the oncology space, the analyst says.